Subcutaneous Ocrelizumab for the Treatment of Relapsing Forms of Multiple Sclerosis: A Budget Impact Model. Porta C, Di Procolo P, Marrazzo G, Belfiore M, Palladino R, Brescia Morra V, Moccia M Pharmacoecon Open. 2026 Aug 03. PMID: 42545439. Abstract CommentRecommendBookmarkWatch
